Introduction
============

In 1956, Tamura, who had studied why Japanese rice wine, "sake", is frequently spoiled by the bacteria *Lactobacillus homohiochi* or *Lactobacillus heterohiochi*, discovered "hiochic acid", a bacterial growth factor, and identified the structure of this chemical to be β-hydroxy-β-methyl-δ-valerolactone.^[@r01])^ In the same year, Wolf *et al.* discovered an acetate-replacing factor for Lactobacilli and identified it as β-hydroxy-β-methyl-δ-valerolactone.^[@r02])^ This compound was also found to be a precursor of cholesterol.^[@r03])^ Later, the standard name of β-hydroxy-β-methyl-δ-valerolactone was changed to mevalonate (MVA).

In the 1960s, Bloch and Lynen established the MVA pathway for cholesterol biosynthesis.^[@r04],[@r05])^ In this pathway, three molecules of acetyl-CoA condense successively to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (Fig. [1](#fig01){ref-type="fig"}). This CoA-derivative is reduced to MVA by HMG-CoA reductase, which is the rate-limiting enzyme of the MVA pathway in humans. Clinically, the specific inhibitors of HMG-CoA reductase, pravastatin and related compounds, are widely used as cholesterol-lowering agents.^[@r06])^ In the next step of the pathway, MVA is phosphorylated twice and finally decarboxylated to form isopentenyl diphosphate (IPP). IPP is then converted to its isomer, dimethylallyl diphosphate (DMAPP), in a reaction that is catalyzed by IPP isomerase. IPP and DMAPP that have been synthesized in the MVA pathway are subsequently used as basic units in the biosynthesis of isoprenoids, such as sterols, carotenoids, and dolichols.

Since the discovery of the MVA pathway, it had been widely accepted that IPP and DMAPP were formed only through this pathway in all living organisms. However, several results inconsistent with the operation of the MVA pathway in certain bacteria had been reported. For example, \[^13^C\]-labeled acetate, a precursor of the MVA pathway, was not incorporated into ubiquinone of *Escherichia coli*^[@r07])^ or into a sesquiterpene pentalenolactone, which had been produced by *Streptomyces chromofuscus* (H. Seto, unpublished results). Feeding experiments with \[U-^13^C\]-labeled glucose and pentalenolactone-producing *Streptomyces exfoliatus* UC5319 showed labeling patterns inconsistent with the MVA pathway.^[@r08],[@r09])^ Furthermore, mevinolin, a specific inhibitor of HMG-CoA reductase, did not inhibit the growth of *E. coli*.^[@r07])^ These results suggested the existence of an alternative pathway for isoprenoid biosynthesis that had been overlooked since the discovery of the MVA pathway.

In 1996, Rohmer identified the first reaction step of an alternative MVA-independent pathway for the formation of IPP and DMAPP in *E. coli*.^[@r10])^ We were encouraged by this pioneering work and began to study the newly discovered pathway. Initially, this pathway was called the "MVA-independent pathway" or "nonmevalonate pathway", but at present, the term "2-*C*-methyl-[d]{.smallcaps}-erythritol 4-phosphate (MEP) pathway" is widely accepted and used because MEP is the first biosynthetic intermediate specific for this pathway. This review focuses on our significant contributions to a comprehensive understanding of the MEP and MVA pathways for the essential metabolic precursors for isoprenoid biosynthesis, IPP and DMAPP.

1. First reaction step, catalyzed by DXP synthase (EC 2.2.1.7)
==============================================================

The initial step in the MEP pathway is the formation of 1-deoxy-[d]{.smallcaps}-xylulose 5-phosphate (DXP) by the condensation of pyruvate and [d]{.smallcaps}-glyceraldehyde 3-phosphate (GAP), and this reaction is catalyzed by DXP synthase (Fig. [2](#fig02){ref-type="fig"}).^[@r10])^ The DXP synthase gene (*dxs*) was first cloned from *E. coli*.^[@r11],[@r12])^ This enzyme has a typical thiamine-binding motif and requires both thiamine and a divalent cation, such as Mg^2+^ or Mn^2+^, for enzyme activity. The reaction preceding this condensation had been found by Yokota *et al.*, who detected the formation of 1-deoxy-[d]{.smallcaps}-xylulose (DX) from pyruvate and [d]{.smallcaps}-glyceraldehyde by pyruvate dehydrogenase of *E. coli* or *Bacillus subtilis*.^[@r13],[@r14])^

We cloned a *dxs* gene homolog from the *Streptomyces* sp. strain CL190 by the polymerase chain reaction using oligonucleotide primers based on highly conserved amino acid sequences.^[@r15])^ Next, we compared the enzymatic properties of the protein product of the *dxs* gene with those of the *E. coli* DXP synthase. We found that although these two enzymes had different origins, they had nearly identical enzymatic properties.

In *E. coli*, DXP is a biosynthetic intermediate not only for IPP and DMAPP but also for thiamine and pyridoxal (Fig. [2](#fig02){ref-type="fig"}).^[@r16])^ This finding indicates that DXP synthase is not the only enzyme specific for the MEP pathway.

2. Ketoclomazone, an inhibitor of DXP synthase
==============================================

Ketoclomazone (2-(2-chlorobenzyl)-4,4-dimethyl-isoxazolidine-3,5-dione) is a derivative of a soil-applied herbicide known as clomazone, dimethazone, or FMC 57020 (Fig. [2](#fig02){ref-type="fig"}).^[@r17])^ Ketoclomazone causes significantly lower chlorophyll and carotenoid levels in barley leaves.^[@r18])^ In addition, 20 µM of ketoclomazone inhibited 47% of the DXP synthase activity in crude extracts from the recombinant *E. coli* expressing a plant *Catharanthus roseus* DXP synthase gene,^[@r19])^ suggesting that ketoclomazone is an inhibitor of DXP synthase. Therefore, ketoclomazone and clomazone have been used as chemical tools to suppress the MEP pathway in plants.^[@r20],[@r21])^ In contrast, ketoclomazone has not been reported to have antibacterial activity, although most bacteria, including pathogens, utilize the MEP pathway for isoprenoid biosynthesis.^[@r22])^ However, we recently demonstrated that ketoclomazone inhibits DXP synthases from *E. coli* and *Haemophilus influenzae* and exhibits antibacterial activity against these bacteria.^[@r23])^ The kinetics of inhibition by ketoclomazone suggests that this chemical binds to an unidentified inhibitor-binding site that differs from the substrate-binding sites for pyruvate and GAP on DXP synthase.

3. Second reaction step, catalyzed by DXP reductoisomerase (EC 1.1.1.267)
=========================================================================

Rohmer and co-workers found that 2-*C*-methylerythritol (ME) was incorporated into *E. coli* cells, which used it as the precursor of the ubiquinone side chain.^[@r24],[@r25])^ Because of this finding, the intramolecular rearrangement of DXP had been assumed to yield a hypothetical rearrangement product, 2-*C*-methylerythrose 4-phosphate, which was subsequently converted to MEP by an unknown reduction process (Fig. [2](#fig02){ref-type="fig"}). For this reason, it was assumed that two enzymes were involved in the formation of MEP from DXP.

To elucidate the details of this mechanism, we decided to clone the gene responsible for MEP synthesis in *E. coli*. We used a unique strategy of screening for *E. coli* mutants that were metabolically blocked between the DXP into MEP synthesis steps of the pathway; specifically, these types of mutants would require MEP or ME for growth.^[@r26])^ In the screening, we added ME to the growth medium and were able to select ten mutants with the desired properties; the addition of ME, but not of DX, to the minimal medium facilitated the growth of those mutants. Only the *yaeM* gene, which had an unknown function, was found to complement these mutations,^[@r27])^ and all ten mutants that needed ME for growth were confirmed by sequencing to be *yaeM*-gene-deficient mutants.^[@r28])^

Next, to confirm whether the *yaeM* gene product (YaeM) was in fact responsible for MEP formation, we constructed a plasmid that would overexpress YaeM in cells. The recombinant protein was purified to apparent homogeneity. Subsequently, the molecular mass of YaeM was estimated to be 42 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 165 kDa by gel filtration chromatography, suggesting that YaeM is probably a homotetramer.

Incubation of the enzyme with DXP in the presence of NADPH resulted in a decrease in the NADPH level in the solution, thereby indicating that the enzyme converted DXP into an unknown reaction product. We purified the reaction product and identified it as MEP on the basis of NMR and MS data.^[@r26])^ This result demonstrated that MEP is synthesized in the presence of NADPH by rearrangement and reduction of DXP in a single step. We designated this enzyme DXP reductoisomerase and renamed the *yaeM* gene "*dxr*".^[@r27])^

As mentioned above, DXP is a precursor not only for IPP and DMAPP but also for thiamine and pyridoxal. Therefore, the reaction catalyzed by DXP reductoisomerase is the committed step in the MEP pathway, and MEP is the first biosynthetic intermediate specific for the MEP pathway.

We identified the catalytic residues of DXP reductoisomerase by analyzing the *E. coli yaeM*-deficient mutants described above. We found that Glu^231^ of the *E. coli* enzyme is important for the conversion of DXP to MEP and that His^153^, His^209^, and His^257^ are important for binding of DXP to the enzyme.^[@r28])^ These results were supported by studies of the three-dimensional structure of DXP reductoisomerase.^[@r29])^

4. Fosmidomycin, an inhibitor of DXP reductoisomerase
=====================================================

DXP reductoisomerase is widely distributed in plants and many bacteria, including pathogens, but not in mammals; therefore, this enzyme could be a target in screens for herbicides and antibacterial drugs.^[@r26],[@r27])^ To screen rapidly for DXP reductoisomerase inhibitors, we constructed an assay system that used a microplate reader.^[@r30])^ Before screening, we performed a literature search to find antibiotics active against *E. coli* and *B. subtilis*, both of which use the MEP pathway, but inactive against *Staphylococcus aureus*, which utilizes the MVA pathway. Our reasoning for doing so was that some inhibitors might have already been reported as antibiotics, and the molecular targets of those drugs may have been unidentified. Fosmidomycin (FR-31564) had the expected antibacterial spectrum and was selected as a candidate for a DXP reductoisomerase inhibitor.

Fosmidomycin has antibacterial activity against most Gram-negative and some Gram-positive bacteria.^[@r31],[@r32])^ Because this antibiotic inhibited menaquinone and carotenoid biosynthesis in *Micrococcus luteus*, it was proposed that this antibiotic inhibited the biosynthesis of isoprenoids.^[@r33])^ From these studies and the structural similarity between fosmidomycin and 2-*C*-methylerythrose 4-phosphate, we assumed that the antibiotic might inhibit DXP reductoisomerase.

In our assay, fosmidomycin strongly inhibited DXP reductoisomerase in a dose-dependent manner with an IC~50~ of 24 nM. The Lineweaver-Burk plot indicated competitive inhibition with a *K*~i~ value of 9.4 nM. Therefore, fosmidomycin is a competitive inhibitor of DXP reductoisomerase.^[@r30])^

Next, we investigated the antibacterial activity of fosmidomycin against *E. coli*. Fosmidomycin completely inhibited bacterial growth at 6.25 µg/ml; however, growth inhibition of *E. coli* by the antibiotic was suppressed when ME was added to the growth medium. In addition, fosmidomycin had no effect on the growth of an *E. coli* DXP reductoisomerase disruptant in the presence of ME.^[@r34])^ The lack of inhibition by fosmidomycin of the disruptant suggested that this mutant lacked a molecular target. From these results, we concluded that fosmidomycin specifically inhibited DXP reductoisomerase in the MEP pathway.^[@r30],[@r34])^

As mentioned above, we identified the catalytic residues of DXP reductoisomerase^[@r28])^ and determined its X-ray crystal structure.^[@r29])^ Analysis of this structure should provide useful information for the development of antibacterial drugs and herbicides.

5. Reaction steps leading to synthesis of IPP from MEP
======================================================

To elucidate the later reactions that lead to the synthesis of IPP from MEP, we initiated studies on the cloning of the genes responsible for the conversion of MEP into IPP. To this end, we employed a unique strategy for preparation of mutants of *E. coli* that were metabolically blocked between the MEP into IPP synthesis steps of the pathway. Because such a mutation would be lethal, we engineered an *E. coli* transformant that possessed an additional biosynthetic pathway for IPP: the MVA pathway.^[@r35])^ This transformant, which possessed genes encoding MVA kinase, phosphomevalonate kinase, and diphosphomevalonate decarboxylase from *Streptomyces* sp. strain CL190, could use part of the MVA pathway for IPP biosynthesis but only in the presence of MVA. The MVA added to the growth medium is converted by these three enzymes into IPP, which is later used by the transformant as a precursor for isoprenoids.

With this transformant as the parental strain, we isolated mutants that had an obligatory requirement of MVA for their growth.^[@r36])^ Thirty-three mutants from approximately 60,000 screened colonies showed the expected phenotypes: the addition of MVA, but not ME, to minimal medium facilitated the growth of the mutants. Thus, these phenotypic features unequivocally showed that the mutants had a defect(s) in the pathway leading to IPP from MEP. Using these mutants, we succeeded in cloning four uncharacterized genes, *ygbP*, *ychB*, *ygbB*, and *gcpE*, that complemented the defects of these mutants in synthesizing IPP from MEP.^[@r36]--[@r38])^ It should be noted that these four genes are apparently needed for IPP biosynthesis in *E. coli*. The distribution patterns of these four genes in bacteria were identical to those of the DXP synthase and DXP reductoisomerase genes of the MEP pathway, thereby supporting the hypothesis that these four genes are essential for this pathway. This bioinformatic analysis also identified the *lytB* gene as an additional candidate responsible for the MEP pathway.^[@r39])^

To identify the functions of the gene products of the *gcpE*, *lytB*, *ygbB*, *ychB*, and *ygbP* genes, we constructed plasmids that overexpressed the gene products of those genes and were able to prepare sufficiently high concentrations of the enzymes to characterize them. Next, we sought to select appropriate reaction conditions for the conversion of MEP into an unknown product by the action of one of the five enzymes.

5.1. Third reaction step, catalyzed by MEP cytidylyltransferase (EC 2.7.7.60).
------------------------------------------------------------------------------

Most of our attempts to disclose the next reaction process were unsuccessful because we could not identify the cofactor of the reaction. This problem was finally overcome by an unexpected finding that the *ygbP* gene product converted MEP into an unknown reaction product in the presence of CTP. We purified the reaction product and identified it by NMR and MS as 4-(cytidine 5′-diphospho)-2-*C*-methyl-[d]{.smallcaps}-erythritol (CDP-ME).^[@r36])^ These results indicated that MEP is converted to CDP-ME in the presence of CTP by the *ygbP* gene product and that this gene product is essential for IPP biosynthesis. We designated the enzyme MEP cytidylyltransferase.^[@r36])^

5.2. Fourth reaction step, catalyzed by CDP-ME kinase (EC 2.7.1.148).
---------------------------------------------------------------------

Next, we demonstrated that the *ychB* gene product converted CDP-ME to an unknown reaction product in the presence of ATP. We purified the reaction product and identified it as 2-phospho-4-(cytidine 5′-diphospho)-2-*C*-methyl-[d]{.smallcaps}-erythritol (CDP-ME2P).^[@r37])^ This result showed that CDP-ME is converted to CDP-ME2P in the presence of ATP by the *ychB* gene product and that this gene product is essential for IPP biosynthesis. We designated the enzyme 4-(cytidine 5′-diphospho)-2-*C*-methyl-[d]{.smallcaps}-erythritol kinase.^[@r37])^

5.3. Fifth reaction step, catalyzed by MECDP synthase (EC 4.6.1.12).
--------------------------------------------------------------------

Finally, we demonstrated that the *ygbB* gene product converted CDP-ME2P to an unknown reaction product. We purified the reaction product and identified it as 2-*C*-methyl-[d]{.smallcaps}-erythritol 2,4-cyclodiphosphate (MECDP).^[@r38])^ The formation of MECDP was concomitant with the elimination of CMP from CDP-ME2P, suggesting that CDP-ME2P is converted to MECDP by the *ygbB* gene product and that this gene product is essential for IPP biosynthesis. We designated this enzyme MECDP synthase.^[@r38])^

It had been reported that certain bacteria, including *Corynebacterium ammoniagenes*, accumulated MECDP under oxidative stress caused by benzyl viologen,^[@r40])^ but there have been no reports on the role of MECDP in the MEP pathway. We showed that MECDP is an intermediate in the MEP pathway for IPP biosynthesis.

Independent of our studies, German researchers found that MECDP is synthesized from MEP by the consecutive actions of the *ygbP*, *ychB*, and *ygbB* gene products^[@r41]--[@r43])^ and that MECDP is efficiently converted into phytoene in the chlomoplasts of *Capsicum annuum* and *Narcissus pseudonarcissus*.^[@r44])^

5.4. Functions of the gcpE and lytB gene products.
--------------------------------------------------

Next, we incubated MECDP with the *gcpE* or *lytB* gene products in the presence of various possible cofactors, such as NADPH, nucleotide triphosphates, or vitamins, with the expectation that the gene product would convert MECDP to an unidentified reaction product. However, our attempts to detect this reaction product *in vitro* were unsuccessful. By contrast, German researchers demonstrated that the *gcpE* and *lytB* genes encoded iron-sulfur (Fe-S) cluster-containing (*E*)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate (HMBDP) synthase (EC 1.17.7.1)^[@r45])^ and Fe-S cluster-containing HMBDP reductase (EC 1.17.1.2), respectively.^[@r46])^ *E. coli* HMBDP synthase converts MECDP into HMBDP in the presence of the flavodoxin/flavodoxin reductase/NADPH system,^[@r45])^ whereas the *E. coli* HMBDP reductase reduces HMBDP in the presence of ferredoxin and NADPH to yield a 5:1 mixture of IPP and DMAPP.^[@r46])^ Both the reactions require complete anaerobic condition.

6. Identification of the MEP pathway genes in plants
====================================================

As mentioned above, we isolated *E. coli* mutants possessing a metabolic block(s) between the steps at which DXP is converted into IPP. These *E. coli* mutants were also used as tools to confirm the functions of the MEP pathway gene products of *Hevea brasiliensis*,^[@r47])^ which is a tree that produces natural rubber, and of *Ginkgo biloba*,^[@r48]--[@r50])^ which is a tree that produces a diterpene ginkgolide. For example, the *H. brasiliensis ygpP* homolog complemented the defect of the *E. coli ygbP*-deficient mutant that was unable to convert MEP into CDP-ME.^[@r47])^

7. Two types of IPP isomerases
==============================

IPP isomerase (EC 5.3.3.2) catalyzes an essential reaction in the MVA pathway by converting IPP to DMAPP. Many IPP isomerase genes (*idi*) were cloned from various organisms such as humans, *Saccharomyces cerevisiae*, *E. coli* and *Rhodobacter capsulatus*. Interestingly, database searches using highly conserved amino acid sequences from previously identified IPP isomerases had failed to detect IPP isomerase in archaea and some bacteria that use the MVA pathway. This failure to detect IPP isomerase in these organisms had suggested the existence of an unidentified type of IPP isomerase, the amino acid sequence of which shared no similarity to those of IPP isomerases.

We cloned a gene cluster encoding enzymes of the MVA pathway from *Streptomyces* sp. strain CL190 and demonstrated that the MVA pathway could function in an *E. coli* strain transformed with this gene cluster.^[@r35],[@r51])^ In addition to the known genes of the MVA pathway, this gene cluster contains an additional open reading frame, *orfD*, which encodes a protein with unknown function. We found the *orfD* homologs in archaea; several Gram-positive bacteria, including *Staphylococcus aureus*; and in the carotenoid biosynthetic gene cluster of *Erwinia herbicola* Eho10.^[@r52])^ Homologs of *orfD* were also detected in the MVA pathway gene cluster in other actinomycetes. These facts led us to assume that *orfD* encodes an unprecedented type of IPP isomerase.

In 2001, we reported that the *orfD* product, when expressed in *E. coli*, catalyzes the isomerization of IPP to produce DMAPP in the presence of both flavin mononucleotide (FMN) and NAD(P)H.^[@r52])^ Based on the enzymatic properties of this enzyme, which are different from those of known IPP isomerases, we proposed that this *orfD* product is a novel type of IPP isomerase with a sequence that has no similarity to those of known IPP isomerases. In addition, we classified the IPP isomerases into two types: Type 2 for the new FMN- and NAD(P)H-dependent enzymes, and type 1, which was known to be present in many organisms.^[@r52])^ We also identified type 2 IPP isomerase in archaea and certain Gram-positive bacteria, such as *S. aureus*, *Streptococcus pneumoniae*, *Streptococcus pyrogenes* and *Enterococcus faecalis*.^[@r52])^ This finding suggested that the type 2 IPP isomerase of *S. aureus* represents an effective target for the screening of anti-staphylococcal drugs.

8. Novel acetoacetyl-CoA synthesizing enzyme found in the Streptomyces MVA pathway gene clusters
================================================================================================

As mentioned above, we identified the MVA pathway gene cluster in several actinomycetes strains.^[@r35])^ The MVA pathway begins with the synthesis of acetoacetyl-CoA, which was first reported to be biosynthesized *via* a thioester-dependent Claisen condensation reaction between two molecules of acetyl-CoA, and is catalyzed by acetoacetyl-CoA thiolase (EC 2.3.1.9). Therefore, acetoacetyl-CoA thiolase was expected to exist in the MVA pathway gene cluster of actinomycetes strains. However, acetoacetyl-CoA thiolase, which is involved in the conversion of acetyl-CoA to acetoacetyl-CoA, is absent. Instead, an open reading frame (for example, *nphT7* of *Streptomyces* sp. strain CL190) that shares homology with β-ketoacyl-(acyl carrier protein) synthase (KAS) III flanks the gene cluster.

In 2010, we reported that NphT7 catalyzes a single condensation of acetyl-CoA and malonyl-CoA to give acetoacetyl-CoA and CoA; however, NphT7 was not able to synthesize acetoacetyl-CoA through the condensation of two molecules of acetyl-CoA.^[@r53])^ Based on the enzymatic properties of NphT7, we proposed that NphT7 was a novel "acetoacetyl-CoA synthase" of the thiolase superfamily. In addition, co-expression of the *nphT7* gene with the HMG-CoA synthase and HMG-CoA reductase genes in the heterologous host *Streptomyces albus* resulted in a 3.5-fold higher production of MVA than when only the HMG-CoA synthase and HMG-CoA reductase genes were expressed.^[@r53])^ This result suggests that *nphT7* could be used to significantly increase the production of commodity isoprenoids, such as carotenoids, Taxol, and artemisinin.

BLAST searches using the NphT7 sequence as a query sequence revealed that NphT7 homologs are widespread in bacteria. We speculate that these NphT7 homologs synthesize CoA derivatives with various acyl groups. Of the homologs, some are located in the biosynthetic gene clusters of unidentified natural products, suggesting that the NphT7-like enzymes are involved in the biosynthesis of acyl-CoA-derived natural products.

9. Diversity of the biosynthesis of IPP and DMAPP
=================================================

Mammals and fungi synthesize IPP and DMAPP using the MVA pathway (Fig. [3](#fig03){ref-type="fig"}). Nearly all archaea, some Gram-positive bacteria, including *Staphylococcus*, *Streptococcus*, *Enterococcus*, *Lactococcus*, *Lactobacillus*, and *Leuconostoc*, and *Myxobacteria* (Gram-negative), also use the MVA pathway, whereas other most bacteria including cyanobacteria synthesize IPP and DMAPP using the MEP pathway. Only a few bacteria use both pathways. In higher plants, the MEP pathway functions in plastids, whereas the MVA pathway functions in cytosols. The species distribution of the MVA and MEP pathways are not associated with those of the type 1 and type 2 IPP isomerases. In bacteria that use the MEP pathway, some have a type 1 enzyme, some have a type 2 enzyme, and others have no IPP isomerase. In contrast, bacteria, as well as most archaea, that use only the MVA pathway usually possess a type 2 IPP isomerase. However, the Q-fever pathogen *Coxiella burnetii* possesses MVA pathway genes and a type 1 IPP isomerase, and the halophilic archaeon *Halobacterium* sp. NRC-1 possesses both functional type 1 and type 2 IPP isomerases, along with the MVA pathway.

It may be interesting to note that some actinomycetes utilize the both pathways. For example, *Streptomyces* sp. strain CL190, a producer of meroterpenoid naphterpin, possesses the genes for both the MVA and MEP pathways. We had proved simultaneous operation of the both pathways for IPP biosynthesis in the strain by detailed tracer experiments using ^13^C-labeled glucose (for the MEP pathway) and ^13^C-labeled acetate (for the MVA pathway) on the formation of menaquinone (a primary metabolite) and naphterpin (a secondary metabolite).^[@r54])^ Another actinomycete, *Kitasatospora griseola*, a producer of diterpene terpentecin, also uses both the MVA and MEP pathways for IPP biosynthesis. We demonstrated that the MEP pathway genes are expressed first and then the MVA pathway genes start to be expressed in the strain.^[@r55])^ Because secondary metabolites such as terpentecin are biosynthesized in the late stage of the growth, the production of terpentecin and the expression of the MVA pathway genes appeared to be synchronized in the producer cells. In addition, the biosynthetic gene clusters of naphterpin and terpentecin flank the MVA pathway gene clusters of each producer.^[@r56],[@r57])^ From these facts, we speculate that the MVA pathway genes in actinomycetes are utilized for the production of the secondary metabolites, such as naphterpin and terpentecin.

Perspective
===========

The MEP pathway is absent in mammals, but this pathway is essential for survival and growth in many pathogenic bacteria, plants, and malaria parasites. Therefore, the enzymes in the MEP pathway could be targets for screening for antibacterial drugs, herbicides, and antimalarial drugs. We expect that our studies will contribute to the development of antimicrobial agents that target the MEP pathway.

Kuzuyama is continuing to study the biosynthesis of some isoprenoids produced by actinomycetes. Yet-undiscovered biosynthetic enzymes for isoprenoids may be buried in the enormous quantity of genetic information, which is accumulating every year. Therefore, we will continue to investigate isoprenoid biosynthesis in microorganisms to illuminate the interplay between functional convergence and divergence in the evolution of metabolic pathways.
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